Navigation Links
Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market
Date:11/19/2010

ve propoxyphene from the market.  Until now, the FDA had concluded that the benefits of propoxyphene for pain relief at recommended doses outweighed the safety risks of the drug.

In January 2009, the FDA held an advisory committee meeting to address the efficacy and safety of propoxyphene. After considering the data submitted with the original drug applications for propoxyphene, as well as subsequent medical literature and postmarketing safety databases, the committee voted 14 to 12 against the continued marketing of propoxyphene products. In making this recommendation, the committee noted that additional information about the drug's cardiac effects would be relevant in weighing its risks and benefits.

In June 2009, the European Medicines Agency (EMEA) recommended that the marketing authorizations for propoxyphene be withdrawn across the European Union. A phased withdrawal of propoxyphene is underway.

In July 2009, the FDA decided to permit continued marketing, but required that a new boxed warning be added to the drug label alerting patients and health care professionals to the risk of a fatal overdose. In addition, the agency required Xanodyne to conduct a new safety study assessing unanswered questions about the effects of propoxyphene on the heart.

The agency now has reviewed the data from that study, which show that, even when taken at recommended doses, propoxyphene causes significant changes to the electrical activity of the heart. These changes, which can be seen on an electrocardiogram (EKG), can increase the risk for serious abnormal heart rhythms that have been linked to serious adverse effects, including sudden death. The available data also indicate that the risk of adverse events for any particular patient (even patients who have taken the drug for many years) is subject to change based on small changes in the health status of the patient, such as dehydration, a change in medications, or decreased kidney function
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Xanodyne Announces Planned President & CEO Succession
2. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
3. Xanodyne Announces Renewed Focus on Pain Management Market
4. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
5. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
6. Boston Scientific Agrees to Sell Neurovascular Business to Stryker
7. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
8. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
9. Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
10. Graymark Healthcare Agrees to Sell Pharmacy Division to Walgreens Creating Pure Play Sleep Apnea Company
11. Fox Insurance Agrees to Pay Delinquent Medicare Part D Claims After Action by Senators Baucus, Grassley, CMS and NCPA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 /CNW/ - On Aug. 20, at ... the Canadian Medical Association (CMA) voted on and approved ... material, including medicinal cannabis. Bedrocan Cannabis Corp., a leading ... the CMA motion. The CMA is quite ... associated with smoking any plant material, including medicinal cannabis. ...
(Date:8/22/2014)... CHICAGO , Aug. 22, 2014   Zacks Equity Research ... the Bull of the Day and Panera (Nasdaq: PNRA - ... Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD ... ) and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The ...
(Date:8/22/2014)... COLORADO SPRINGS, Colo. , Aug. 22, 2014 ... Company specializing in cannabis formulation-based drug development and ... of UFCM iCare,s third international medical cannabis conference ... Strasbourg, France , on October ... experts with other stakeholders, such as researchers, health ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
Cached Medicine Technology:ResearchDx Launches Contract Diagnostics Organization (CDO) 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4
(Date:8/22/2014)... (EGFR) mutations found in the circulating free tumor DNA ... cancer (NSCLC) patients correlates well with the EGFR mutations ... inhibitor (TKI) therapy is approved for EGFR activating mutation ... determining mutation status is with DNA derived directly from ... A more abundant and less invasive source of tumor ...
(Date:8/22/2014)... DC (PRWEB) August 22, 2014 Paying ... little easier in the coming year for four nurse ... the National League for Nursing Foundation for Nursing ... – will share $28,000, $10,000 more than in 2013, ... Ann Kerr Endowment and Elizabeth Isaac Marcil Endowment Funds, ...
(Date:8/22/2014)... August 22, 2014 Advancements in ... some clinical applications due to their cost-effectiveness, non-invasiveness, ... innovations in ultrasound, such as the evolution of ... to keep the market moving throughout 2014 and ... can enhance not only the point-of-care (POC) testing ...
(Date:8/22/2014)... Eagerly embracing intended parents around the ... now offers the top male infertility programs — run ... fertility network of IVFinMexico.com continues to shape ... care, female and male infertility, advanced research and education. ... so eminently set by company CEO and Founder Tolga ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
Breaking Medicine News(10 mins):Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), announces ... ), "We have leased, fitted and established ... will allow us to streamline the process,of new ... facility will house,both electronic and pharmaceutical laboratories," announced ...
... &, Presidential Election May Mean for Private Equity in 2008, Jan. ... the ... credit markets in,turmoil, the economy in a seeming slowdown and a presidential ... Outlook,Conference on January 29-30 at the Grand Hyatt in New York to ...
... men with chronic anxiety are at substantially higher risk, experts ... who suffer from chronic anxiety substantially increase their risk of ... stress has been linked to an increased risk of heart ... been identified as a risk factor also. , "There is ...
... 2 diabetes are often advised to cut out sucrose (table ... has been questioned by some researchers who suggest that moderate ... the diet of patients with diabetes. Now a new study ... It showed that patients who increased their daily sugar intake ...
... tendon grafts loaded with gene therapy may soon ... that has eluded surgeons to date. According to ... Therapy, a new graft technique may provide the ... can reorganize as it heals. Such tissue-engineering approaches ...
... Haemonetics,Corporation (NYSE: HAE ) will announce its Q3FY08 earnings on January ... Conference Call Dial-In Information (888) 802-8577 ... ID: 30405896 This call will be ... dial:, (800) 642-1687 (US & Canada) ...
Cached Medicine News:Health News:ReBuilder Medical Technologies, Inc. Expands R&D of New Products 2Health News:Private Equity's Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference 2Health News:Anxiety Raises Heart Attack Risk 2Health News:Anxiety Raises Heart Attack Risk 3Health News:Carrot cake study on sugar in type 2 diabetes 2Health News:Freeze-dried tendon implants prove effective in early studies 2Health News:Freeze-dried tendon implants prove effective in early studies 3Health News:Freeze-dried tendon implants prove effective in early studies 4Health News:Freeze-dried tendon implants prove effective in early studies 5
... Finnpipette BioControl multichannel has ... as the single channel ... fits all seven multichannel ... tip cone modules. Both ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
... a 384 Well Plate at Once , To ... you need a pipettor that can adapt to ... get with our 16-channel Impact pipettor., Available with ... was specifically designed to allow you to transfer ...
Medicine Products: